Full Product Name
CLN8 Antibody (C-term)
Product Synonym Names
Protein CLN8; CLN8; C8orf61
Product Gene Name
anti-CLN8 antibody
[Similar Products]
Antibody/Peptide Pairs
CLN8 peptide (MBS9223706) is used for blocking the activity of CLN8 antibody (MBS9205795)
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
Immunogen Sequence Positions
251-280
3D Structure
ModBase 3D Structure for Q9UBY8
Specificity
This CLN8 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 251-280 amino acids from the C-terminal region of human CLN8.
Purity/Purification
Peptide Affinity Purified Rabbit Polyclonal Antibody (Pab)
Form/Format
Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.
Concentration
Vial Concentration: 0.45 (lot specific)
Antigen Type
Synthetic Peptide
Preparation and Storage
Maintain refrigerated at 2-8 degree C for up to 6 months. For long term storage store at -20 degree C in small aliquots to prevent freeze-thaw cycles.
Other Notes
Small volumes of anti-CLN8 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
anti-CLN8 antibody
This gene encodes a transmembrane protein belonging to a
family of proteins containing TLC domains, which are postulated to
function in lipid synthesis, transport, or sensing. The protein
localizes to the endoplasmic reticulum (ER), and may recycle
between the ER and ER-Golgi intermediate compartment. Mutations in
this gene are associated with progressive epilepsy with mental
retardation (EMPR), which is a subtype of neuronal ceroid
lipofuscinoses (NCL). Patients with mutations in this gene have
altered levels of sphingolipid and phospholipids in the brain.
Product Categories/Family for anti-CLN8 antibody
Metabolism; Neuroscience; Signal Transduction
Applications Tested/Suitable for anti-CLN8 antibody
Western Blot (WB), ELISA (EIA)
Application Notes for anti-CLN8 antibody
WB~~1:1000
Western Blot (WB) of anti-CLN8 antibody
CLN8 Antibody (C-term) western blot analysis in HL-60 cell line lysates (35ug/lane).This demonstrates the CLN8 antibody detected the CLN8 protein (arrow).

NCBI/Uniprot data below describe general gene information for CLN8. It may not necessarily be applicable to this product.
NCBI Accession #
NP_061764.2
[Other Products]
NCBI GenBank Nucleotide #
NM_018941.3
[Other Products]
UniProt Primary Accession #
Q9UBY8
[Other Products]
UniProt Secondary Accession #
Q86U71; Q96I95[Other Products]
UniProt Related Accession #
Q9UBY8[Other Products]
NCBI Official Full Name
protein CLN8
NCBI Official Synonym Full Names
ceroid-lipofuscinosis, neuronal 8
NCBI Official Symbol
CLN8??[Similar Products]
NCBI Official Synonym Symbols
EPMR; C8orf61
??[Similar Products]
NCBI Protein Information
protein CLN8
UniProt Protein Name
Protein CLN8
UniProt Gene Name
CLN8??[Similar Products]
UniProt Synonym Gene Names
C8orf61??[Similar Products]
UniProt Entry Name
CLN8_HUMAN
NCBI Summary for CLN8
This gene encodes a transmembrane protein belonging to a family of proteins containing TLC domains, which are postulated to function in lipid synthesis, transport, or sensing. The protein localizes to the endoplasmic reticulum (ER), and may recycle between the ER and ER-Golgi intermediate compartment. Mutations in this gene are associated with progressive epilepsy with mental retardation (EMPR), which is a subtype of neuronal ceroid lipofuscinoses (NCL). Patients with mutations in this gene have altered levels of sphingolipid and phospholipids in the brain. [provided by RefSeq, Jul 2008]
UniProt Comments for CLN8
CLN8: Could play a role in cell proliferation during neuronal differentiation and in protection against cell death. Defects in CLN8 are the cause of neuronal ceroid lipofuscinosis type 8 (CLN8). A form of neuronal ceroid lipofuscinosis with onset in childhood. Neuronal ceroid lipofuscinoses are progressive neurodegenerative, lysosomal storage diseases characterized by intracellular accumulation of autofluorescent liposomal material, and clinically by seizures, dementia, visual loss, and/or cerebral atrophy. The lipopigment patterns observed most often in neuronal ceroid lipofuscinosis type 8 comprise mixed combinations of granular, curvilinear, and fingerprint profiles. Defects in CLN8 are the cause of neuronal ceroid lipofuscinosis type 8 Northern epilepsy variant (CLN8NE). A form of neuronal ceroid lipofuscinosis clinically characterized by epilepsy that presents between 5 and 10 years of age with frequent tonic-clonic seizures followed by progressive mental retardation. Visual loss is not a prominent feature. Intracellular accumulation of autofluorescent material results in curvilinear and granular profiles on ultrastructural analysis.
Protein type: Cell development/differentiation; Endoplasmic reticulum; Membrane protein, multi-pass; Apoptosis; Membrane protein, integral
Chromosomal Location of Human Ortholog: 8p23
Cellular Component: endoplasmic reticulum membrane; ER-Golgi intermediate compartment membrane; mitochondrion; endoplasmic reticulum; integral to membrane; ER-Golgi intermediate compartment
Biological Process: mitochondrial membrane organization and biogenesis; lipid biosynthetic process; photoreceptor cell maintenance; ***** walking behavior; age-dependent response to oxidative stress; neuromuscular process controlling posture; negative regulation of transferase activity; visual perception; neurofilament cytoskeleton organization and biogenesis; somatic motor neuron differentiation; phospholipid metabolic process; ceramide biosynthetic process; protein catabolic process; neuromuscular process controlling balance; associative learning; negative regulation of proteolysis; cholesterol metabolic process; nervous system development; glutamate uptake during transmission of nerve impulse; social behavior; lipid transport; cellular protein catabolic process; lysosome organization and biogenesis; retina development in camera-type eye; musculoskeletal movement; ceramide metabolic process; regulation of cell size; negative regulation of apoptosis
Disease: Ceroid Lipofuscinosis, Neuronal, 8; Ceroid Lipofuscinosis, Neuronal, 8, Northern Epilepsy Variant
Product References and Citations for anti-CLN8 antibody
Reinhardt, K., et al. Clin. Genet. 77(1):79-85(2010)
Vantaggiato, C., et al. Hum. Mutat. 30(7):1104-1116(2009)
Kousi, M., et al. Brain 132 (PT 3), 810-819 (2009) :
Striano, P., et al. Epilepsy Behav 10(1):187-191(2007)
Hermansson, M., et al. J. Neurochem. 95(3):609-617(2005)
Research Articles on CLN8
1. This study highlights a close interaction between CLN5/CLN8 proteins, and their role in sphingolipid metabolism. Our findings suggest that CLN5p/CLN8p most likely are positive modulators of CerS1 and/or CerS2.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.